Skip to content
Search

Governance

Executive Team

  • Patrick ALEXANDRE

    Founder and CEO
    Chairman of the Executive Board

    35 years of experience
    Formerly with Arcelor
    and Laboratoires Fournier
    Founder in 2001

    Patrick ALEXANDRE on LinkedIn

    Patrick ALEXANDRE

    Founder and CEO · Chairman of the Executive Board

    Patrick ALEXANDRE is the Founder and Chairman of the Executive Board of CROSSJECT.

    A graduate of SUPÉLEC, he led R&D teams in the steel industry for over 10 years before transitioning to the pharmaceutical industry, where he worked for more than 15 years.

    Patrick ALEXANDRE spearheaded the design and development of needle-free injection technology at LABORATOIRES FOURNIER starting in 1997. This activity was transferred to CROSSJECT upon its creation in 2001.

    He served as General Manager before being appointed Chairman of the Executive Board in 2012.

  • Isabelle LIEBSCHUTZ

    Director of Quality & Regulatory Affairs
    Member of the Executive Board

    26 years of experience
    Formerly with Fournier Labs, Solvay, Plasto Santé
    Joined in 2013

    Isabelle LIEBSCHUTZ on LinkedIn

    Isabelle LIEBSCHUTZ

    Director of Quality & Regulatory Affairs · Member of the Executive Board

    Isabelle LIEBSCHUTZ joined CROSSJECT in 2013, bringing over 17 years of experience in the pharmaceutical industry.

    She spent 5 years as part of the “Formulation and Development” team at LABORATOIRES FOURNIER and 7 years as Quality Assurance Manager for the production of transdermal devices, outsourced products, and quality systems on behalf of LABORATOIRES FOURNIER/SOLVAY, covering both European and U.S. markets.

    From 2008 to 2013, Isabelle LIEBSCHUTZ held the position of Responsible Pharmacist at a contract manufacturing organization (CMO) specializing in the industrialization and manufacturing of pharmaceutical products and medical devices.

  • Didier MORIN

    Industrial Director

    28 years of experience
    Formerly with IDS, Axess Vision
    Joined in 2023

    Didier MORIN on LinkedIn

    Didier MORIN

    Industrial Director

    Didier MORIN joined CROSSJECT in 2023, bringing extensive experience in industrial operations, production, and R&D. He excels in managing multidisciplinary teams to implement global industrial strategies across various sectors, including medical devices, automotive, and food industries.

    Previously, Didier MORIN served for 10 years as Plant Manager and General Manager at IDS and AXESS VISION, two companies specializing in medical devices, where he significantly improved production and operational efficiency.

    He holds a Master’s degree in engineering from the Ecole Nationale de Belfort.

  • Lionel SELTZ

    Chief Financial Officer

    28 years of experience
    Formerly with Mars,
    IQVIA, Cegedim
    Joined in 2026

    Lionel SELTZ on LinkedIn

    Lionel SELTZ

    Chief Financial Officer

    Lionel SELTZ brings close to 30 years of international experience across finance, strategy and operations, gained in global organizations and listed companies in life sciences, healthcare and technology.

    Before joining CROSSJECT, he served as CFO North Europe at Antech Diagnostics, a division of Mars Science & Diagnostics. He also held several senior finance and executive leadership positions in innovative and fast-growing environments, notably at Intrasense, as well as within leading organizations such as IQVIA and Cegedim. Over the course of his career, he held leadership responsibilities in both France and Asia in demanding international environments.

    Throughout his career, Lionel SELTZ has developed recognized expertise in strategic finance, fundraising, M&A, post-merger integration, business transformation, performance improvement and international development. He has worked both in companies listed on Euronext Growth and in regulated market environments, with a strong international dimension.

    At CROSSJECT, he brings this experience to support the Group’s financial strategy, growth structuring, international development and long-term value creation.

  • Olivier LACOMBE

    Pharma Development Director

    18 years of experience
    Formerly with Fournier Labs, Abbott, Solvay, Inventiva
    Joined in 2021

    Olivier LACOMBE on LinkedIn

    Olivier LACOMBE

    Pharma Development Director

    Olivier LACOMBE has over 20 years of experience in pharmaceutical R&D, with significant expertise in managing multidisciplinary projects and interactions with regulatory authorities and partners.

    He has held leadership positions in several major pharmaceutical companies, including FOURNIER, SOLVAY, ABBOTT, and more recently, INVENTIVA, where he served as Director of Research Projects in both clinical and non-clinical phases. He has also led operational departments, participated in steering committees, and contributed to multiple international project teams focused on various aspects of drug development.

    As Director of Pharmaceutical Development, Olivier LACOMBE is one of the key points of contact for CROSSJECT’s partners.

    He holds a PhD in pharmacology/pharmacokinetics from UNIVERSITÉ PAUL SABATIER TOULOUSE.

  • Tony TIPTON

    COO - USA

    27 years of experience
    Formerly with Xequel Bio, Santen, Eyevance, Sunovion, Galderma, Sanofi-Dermik
    Joined in 2024

    Tony TIPTON on LinkedIn

    Tony TIPTON

    COO - USA

    With over 25 years of experience in key sectors of the commercial pharmaceutical industry, he brings expertise in corporate governance and business development, market access, sales management, marketing, and commercial operations.

    He joined CROSSJECT after serving as Director of Commercial Operations at XEQUEL BIO, where he was responsible for commercialization strategy and pre-commercial activities for assets funded by BARDA and the U.S. NATIONAL INSTITUTES OF HEALTH (NIH), as well as acquired commercial assets.

    Throughout his career, he has held multiple leadership positions in commercial roles within major international specialized pharmaceutical companies. Notably, he served as interim U.S. Commercial Director and Vice President of Market Access and Commercial Channels at SANTEN PHARMACEUTICALS following the acquisition of EYEVANCE PHARMACEUTICALS. In this role, Tony TIPTON assumed various commercial responsibilities for the U.S. region and generated over $70 million in gross revenue for U.S. commercial operations.

    He also served as Account Director at SUNOVION PHARMACEUTICALS, where he was responsible for integrated health systems and launched a new epilepsy treatment, APTIOM. At GALDERMA LABORATORIES, he held several positions in sales and marketing.

Supervisory Board

Philippe MONNOT

Chairman of the Supervisory Board

Philippe MONNOT is the co-leader of Gemmes Venture, which he co-founded in 1999. GEMMES VENTURE is a founding member of various companies in the healthcare sector (ASTEN SANTÉ, H2AD TELEHEALTH, VIVALIB), as well as in digital services, fintech, and cleantech. GEMMES VENTURE was also the first shareholder of CROSSJECT. Philippe MONNOT is a graduate of EM LYON.

Eric NEMETH

Member

Eric NEMETH is a professional investor, Advisor to STEED CAPITAL, and founder of MACEINVEST1, a business angel fund, following a career in the banking and financial sector.

He served as a member of the Executive Committee of DEUTSCHE BANK in France, CEO of WORMS BANK and DETROYAT ASSOCIÉS, after working for STERN BANK and BANEXI.

Eric NEMETH began his career at the SAINT-GOBAIN GROUP, where he held various positions, including Head of Corporate Finance and Investor Relations, from 1982 to 1989.

Daniel TEPER

Member

Daniel TEPER is a pharmaceutical industry leader and entrepreneur based in the United States. He holds a Doctor of Pharmacy degree from the UNIVERSITY of PARIS SACLAY and a Master of Business Administration from INSEAD.

He has held executive roles in several pharmaceutical companies, including GLAXO LABORATORIES and DELAGRANGES. He was also a Global Partner at EURORSCG HAVAS HEALTH and a Partner at ISO HEALTHCARE CONSULTING.

Daniel TEPER is the Founder of multiple companies, including WINTEC PHARMA and IMMUNE PHARMACEUTICALS. He currently serves as the CEO of CYTOVIA THERAPEUTICS, where he is the principal Founder.

Dr Jean-François LOUMEAU

Member

Dr. Jean-Francois LOUMEAU practiced medicine from 1981 to 1985 before holding numerous roles in the pharmaceutical industry in France and internationally, particularly in commercial fields and subsidiary management, from 1985 to 2005.

He served on the Supervisory Board of a French pharmaceutical manufacturing company from 2007 to 2013. Since then, he has held Non-Executive Director positions in unlisted pharmaceutical companies in France and Europe, as well as advisory roles for private equity funds in acquisitions of industrial sites or pharmaceutical product portfolios.

Recently, he joined the Advisory Board of E-SANA, a young French start-up specializing in ultraportable diagnostic tools for POCT (Point-Of-Care Tests).

Dr. Jean-Francois LOUMEAU graduated from the FACULTY OF MEDICINE PARIS VI – PIERRE AND MARIE CURIE UNIVERSITY. He also holds a degree from ESSEC BUSINESS SCHOOL (1985).

Dr Yannick PLÉTAN

Member

Dr. Yannick PLETAN practiced medicine as Head of the Pulmonology Department at the Menton Hospital and collaborated on numerous research projects with INSERM.

He then held executive positions in the pharmaceutical industry for over 20 years (SANOFI, INSTITUT DE RECHERCHE PIERRE FABRE, PFIZER, ROCHE), contributing to successful product launches.

Dr. PLETAN now advises innovative biotech companies in Europe and the United States on development strategies, as well as medical and regulatory approaches.

Two employee representatives, appointed by the Works Council (CSE), participate in the Supervisory Board meetings

The CSE (Social and Economic Committee) is a representative body for employees in French companies, tasked with protecting workers’ interests in matters related to working conditions, health, and safety.

It consolidates the functions of the former works councils, staff delegates, and the Health, Safety, and Working Conditions Committee (CHSCT). The CSE has both advisory and decision-making roles on various aspects of corporate life.